Cargando…
Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors
The purpose of this narrative review was to provide an overview that allows readers to improve their understanding of hemophilia A, which is considered a genetic disease with a high impact on the quality of life of people who suffer from it is considered one of the diseases with the highest cost for...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944491/ https://www.ncbi.nlm.nih.gov/pubmed/36810557 http://dx.doi.org/10.3390/hematolrep15010014 |
_version_ | 1784891927103012864 |
---|---|
author | Sarmiento Doncel, Samuel Díaz Mosquera, Gina Alejandra Cortes, Javier Mauricio Agudelo Rico, Carol Meza Cadavid, Francisco Javier Peláez, Ronald Guillermo |
author_facet | Sarmiento Doncel, Samuel Díaz Mosquera, Gina Alejandra Cortes, Javier Mauricio Agudelo Rico, Carol Meza Cadavid, Francisco Javier Peláez, Ronald Guillermo |
author_sort | Sarmiento Doncel, Samuel |
collection | PubMed |
description | The purpose of this narrative review was to provide an overview that allows readers to improve their understanding of hemophilia A, which is considered a genetic disease with a high impact on the quality of life of people who suffer from it is considered one of the diseases with the highest cost for health systems (In Colombia it is part of the five diseases with the greatest economic impact). After this exhaustive review, we can see that the treatment of hemophilia is on the way to precision medicine, which involves genetic variables specific to each race and ethnicity, pharmacokinetics (PK), as well as environmental factors and lifestyle. Knowing the impact of each of these variables and their relationship with the efficacy of treatment (prophylaxis: regular infusion of the missing clotting factor VIII in order to prevent spontaneous bleeding) will allow for individualizing the medical behavior in a cost-effective way. For this is required to build more strong scientific evidence with statistical power that allows us to infer. |
format | Online Article Text |
id | pubmed-9944491 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99444912023-02-23 Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors Sarmiento Doncel, Samuel Díaz Mosquera, Gina Alejandra Cortes, Javier Mauricio Agudelo Rico, Carol Meza Cadavid, Francisco Javier Peláez, Ronald Guillermo Hematol Rep Review The purpose of this narrative review was to provide an overview that allows readers to improve their understanding of hemophilia A, which is considered a genetic disease with a high impact on the quality of life of people who suffer from it is considered one of the diseases with the highest cost for health systems (In Colombia it is part of the five diseases with the greatest economic impact). After this exhaustive review, we can see that the treatment of hemophilia is on the way to precision medicine, which involves genetic variables specific to each race and ethnicity, pharmacokinetics (PK), as well as environmental factors and lifestyle. Knowing the impact of each of these variables and their relationship with the efficacy of treatment (prophylaxis: regular infusion of the missing clotting factor VIII in order to prevent spontaneous bleeding) will allow for individualizing the medical behavior in a cost-effective way. For this is required to build more strong scientific evidence with statistical power that allows us to infer. MDPI 2023-02-16 /pmc/articles/PMC9944491/ /pubmed/36810557 http://dx.doi.org/10.3390/hematolrep15010014 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Sarmiento Doncel, Samuel Díaz Mosquera, Gina Alejandra Cortes, Javier Mauricio Agudelo Rico, Carol Meza Cadavid, Francisco Javier Peláez, Ronald Guillermo Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors |
title | Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors |
title_full | Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors |
title_fullStr | Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors |
title_full_unstemmed | Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors |
title_short | Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors |
title_sort | haemophilia a: a review of clinical manifestations, treatment, mutations, and the development of inhibitors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944491/ https://www.ncbi.nlm.nih.gov/pubmed/36810557 http://dx.doi.org/10.3390/hematolrep15010014 |
work_keys_str_mv | AT sarmientodoncelsamuel haemophiliaaareviewofclinicalmanifestationstreatmentmutationsandthedevelopmentofinhibitors AT diazmosqueraginaalejandra haemophiliaaareviewofclinicalmanifestationstreatmentmutationsandthedevelopmentofinhibitors AT cortesjaviermauricio haemophiliaaareviewofclinicalmanifestationstreatmentmutationsandthedevelopmentofinhibitors AT agudeloricocarol haemophiliaaareviewofclinicalmanifestationstreatmentmutationsandthedevelopmentofinhibitors AT mezacadavidfranciscojavier haemophiliaaareviewofclinicalmanifestationstreatmentmutationsandthedevelopmentofinhibitors AT pelaezronaldguillermo haemophiliaaareviewofclinicalmanifestationstreatmentmutationsandthedevelopmentofinhibitors |